Supervivencia de cáncer colorrectal en un centro oncológico de Colombia. Estudio de cohorte histórica

Campo-Sánchez, S.M.; Camargo-Trillos, J.; Calle-Ramírez, J.A.; Gómez-Wolff, L.R.; Sánchez-Patiño, L.A.; García-García, Héctor Iván

doi:10.1016/j.rgmx.2018.04.002

Cited by 11 publications

(15 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, there were no signi cant differences in the mean age of the patients, 61.43 years, similar to patient ages re ected in other studies, nor in the predominant sex, masculine, which could be related to their higher exposure to risk factors and the protective effect of female hormones. [4,32] However, overall survival at 48 months was 84.2%, higher than that reported in other studies. [4,33,34] As regards anatomic pathology, 98.27% of the tumours showed histology compatible with adenocarcinoma, and only one with lymphoma.…”

Section: Discussioncontrasting

confidence: 56%

“…[4,32] However, overall survival at 48 months was 84.2%, higher than that reported in other studies. [4,33,34] As regards anatomic pathology, 98.27% of the tumours showed histology compatible with adenocarcinoma, and only one with lymphoma.…”

Section: Discussioncontrasting

confidence: 56%

“…[2.3] This increased incidence has been detected across the world, being especially associated with ageing population in all countries, including Spain. [1] Globally, colorectal cancer (CRC) ranks third behind breast and lung cancer in the number of new cases (10.2% of all neoplasms), [1] with an incidence of 9.7% and a prevalence of 10.9%, [4] being the cancer of the digestive tract more frequent in most countries of the world. [5] In Spain, colorectal cancer is the most commonly diagnosed cancer (14% of total cancer diagnoses -37,172 cases detected in 2018), followed by prostate (12%), lung (12%) and breast cancer (10%).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Colorectal Cancer Prevalence and Survival in Castilla La Mancha (Spain). A Pilot Study

González¹,

Ibáñez²,

Sotos³

2021

Preprint

View full text Add to dashboard Cite

Background: Colorectal cancer is the most commonly diagnosed cancer type and the second cause of cancer death in Spain. The primary risk factor for colorectal cancer is age, with 90% of all diagnosed patients aged over 50 years. Prognosis mainly depends on tumour stage. Aim: Conduct a pilot Colorectal Cancer prevalence and survival study in Cuenca (Spain) since there are almost no studies based on small populations. This is the first pilot study about survival in screening of colorectal cancer carried out in hospitals in Castilla La Mancha. Methods and Results: Retrospective descriptive cohort study was performed to include patients with colorectal cancer diagnosed by colonoscopy between May 2015 and April 2016, and who were followed up for 48 months. The study considered sociodemographic and clinical data of the patients. Survival curves were estimated using the Kaplan-Meier method. The proportional hazard rate associated with age, gender, stage and presence of metastasis was calculated using the Cox regression method. 57 patients were included in the study. The mean follow-up was 45.5 months. Ten patients died during the study, in seven cases the cause was colorectal cancer. The percentage of patients alive at 48-month follow-up were 82.4%. Conclusion: Colon cancer is a high-prevalence pathology, with adenocarcinoma being the most common histology. The results seem to indicate that it affects men more frequently, mortality rises with tumour stage at diagnosis and declines with use of chemotherapy. We present a pilot study that could justify large-scale epidemiological studies for the regional surveillance and evolution of colorectal cancer in Spain.

show abstract

Section: Discussioncontrasting

confidence: 56%

Section: Discussioncontrasting

confidence: 56%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Colorectal Cancer Prevalence and Survival in Castilla La Mancha (Spain). A Pilot Study

González¹,

Ibáñez²,

Sotos³

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC), as one of the highly malignant cancers with a poor prognosis, leads to a large number of deaths worldwide, and millions of people get CRC every year. 1,2 CRC mostly affects the rectum, the sigmoid colon and the distal part of the descending colon. 3 Colorectal tumorigenesis begins with a progressive transformation of epithelial cells.…”

Section: Introductionmentioning

confidence: 99%

MiR‐4319 suppresses colorectal cancer progression by targeting ABTB1

Huang

Zhang

et al. 2019

UEG Journal

View full text Add to dashboard Cite

Background Colorectal cancer is one of the highly malignant cancers with a poor prognosis. The exact mechanism of colorectal cancer progression is not completely known. Recently, microRNAs (miRNAs, miRs) were suggested to participate in the regulation of multiple cancer development, including colorectal cancer. Methods MiR-4319 expression in colorectal cancer patient samples was detected by real-time polymerase chain reaction. MiR-4319 was knocked down in the colorectal cancer cells by siRNA transfection to study the role of miR-4319 in the cell cycle and proliferation of colorectal cancer cells. Results MiR-4319 expression was found to be inverse correlated with survival in colorectal cancer patients. Overexpression of miR-4319 markedly reduced the proliferation of colorectal cancer cells and altered cell cycle distribution. A further experiment showed that ABTB1 is the target gene of miR-4319. MiR-4319 was regulated by PLZF. Conclusion Our studies indicated that reduced expression of miR-4319 was correlated with poor prognosis in colorectal cancer patients; miR-4319 also suppressed colorectal cancer cell proliferation by targeting ABTB1. ABTB1 might become an excellent therapeutic target for colorectal cancer treatment.

show abstract

“…Colon cancer is one of the most common malignancies worldwide, in 2018, with an agestandardized rate of 11.1 per 100,000 person-years, ranked fourth in the estimated cancer incidence rates; being the fourth more frequently presented in women and the sixth in men, also worldwide (1). The prognosis of colon cancer is related to the pathological stage at diagnosis, with 5-year survival ranging from 74% for stage I to 5.7% for stage IV (2).…”

Section: Introductionmentioning

confidence: 99%

Expression of Osteopontin and Cyclooxygenase-2 in relation to cellular proliferation, in non-tumor colonic mucosa, colonic adenomas and colon adenocarcinoma.

2021

View full text Add to dashboard Cite

Introduction: the participation of Cyclooxygenase-2 (COX-2) and Osteopontin has been postulated in the development of colon cancer, which play an important role in the progression and could be biomarkers for its prognosis, but their role remains controversial. Objective: to determine and to compare the expression of Osteopontin and COX-2 in non-tumor colonic mucosa, colonic adenomas and colon adenocarcinoma, in relation to the cell proliferation index. Methods: the immunohistochemical expression of COX-2, Osteopontin and Ki-67 in formalin fixed paraffin embedded tissue of non-tumor colonic mucosa, colonic adenomas and colon adenocarcinoma were determined and compared. Results: were included 65 cases: 19 of non-tumor colonic mucosa, 13 colonic adenomas and 33 colon adenocarcinomas. There was increased expression of Ki-67 in dysplastic and tumor cells. There was positive expression for COX-2 in adenomas (30.7%) and adenocarcinomas (27.3%), without significant difference between non- tumor colonic mucosa, adenomas and adenocarcinoma (p = 0.888). Osteopontin showed more frequent positivity in adenocarcinomas (72.7%) and adenomas (84.6%) than in non-tumor mucosa (10.5%), (p = <0.0001), without significant differences in its expression between subtypes and grades of adenoma dysplasia, nor between grades of differentiation, extension and proliferation of adenocarcinomas. There was a significant association between Osteopontin expression and the cell proliferation index. No association was observed between the expression of COX-2 and Osteopontin (p = 0.96). Conclusions: Osteopontin overexpression in colon adenocarcinoma and adenomas in comparison with non-tumor colonic mucosa, and its significant relationship with the cell proliferation index, constitutes additional evidence of its possible participation in the colonic carcinogenesis process.

show abstract

Supervivencia de cáncer colorrectal en un centro oncológico de Colombia. Estudio de cohorte histórica

Abstract: The clinical characteristics and treatment of patients were similar to those found in other studies. Two-year survival was higher than in other Colombian reports and 5-year survival was lower than that observed in developed countries.

Cited by 11 publications

References 49 publications

Colorectal Cancer Prevalence and Survival in Castilla La Mancha (Spain). A Pilot Study

Colorectal Cancer Prevalence and Survival in Castilla La Mancha (Spain). A Pilot Study

MiR‐4319 suppresses colorectal cancer progression by targeting ABTB1

Expression of Osteopontin and Cyclooxygenase-2 in relation to cellular proliferation, in non-tumor colonic mucosa, colonic adenomas and colon adenocarcinoma.

Contact Info

Product

Resources

About